Beschreibung:
<jats:p><jats:bold>Abstract:</jats:bold> This study was aimed at evaluating the digestive tolerance of the new antiosteoporotic drug, strontium ranelate, and to compare it to that of another strontium salt, strontium chloride (SrCl<jats:sub>2</jats:sub>). Strontium ranelate, SrCl<jats:sub>2</jats:sub>, or placebo were administered orally (capsules) to 3 groups of 2 male and 2 female cynomolgus monkeys (<jats:italic>Macaca fascicularis</jats:italic>) once a day for 7 days at a dose of 2 g/day, which is the recommended therapeutic dose in man. Endoscopic examination of the oesophagus, the stomach and the first part of the duodenum was performed on fasted animals approximately 3 hr after the first (Day 1) and last dosing (Day 7), and, on Day 8 and Day 14 in case of lesions on Day 7. Strontium ranelate did not induce any acute or subchronic toxic effect on the gastric mucosa, the oesophagus and the first part of the duodenum. On the contrary, acute and superficial damages were noted on all animals receiving SrCl<jats:sub>2</jats:sub> such as haemorrhagic and erosive lesions (formation of an ulcer in one male and a marked congestive antritis in one female). These effects were reversible after cessation of treatment. The microscopic examination of biopsies sampled at the site of gastric lesions revealed moderate granulocyte infiltration, indicating a local irritating origin of the lesions. Strontium ranelate by oral route is safe for the gastric mucosa while SrCl<jats:sub>2</jats:sub> induced superficial and reversible lesions.</jats:p>